CSPC Pharmaceutical Group (HKG:1093) obtained clinical trial approval for the SYH2092 injection from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.
The product has the potential to bring significant clinical benefits for weight management in patients with obesity and improve glycaemic control in patients with type 2 diabetes mellitus.